Milan (ots/PRNewswire) - The new platform will be presented at the
next EACR Liquid Biopsy conference to be held in Bergamo, Italy, on
May 24th-26th, 2022
Tethis S.p.A announces the release of See.d®, the first universal
blood sample preparator for liquid biopsy analysis. This innovative
technology performs a completely automated and standardized
preparation of a blood sample at the point of blood collection.
Cellular fraction is gently stabilized on proprietary, nanocoated SBS
slides for rare cell detection, including CTCs, while plasma is made
available for the analysis of cell-free content.
See.d® is for professional use but does not require specialized lab
technicians and most importantly there is no need of whole blood
shipment and preservation, one of the most critical points of liquid
biopsy pre-analytical workflows. See.d® processes fresh blood
collected in EDTA tubes shortly after collection (within 4 to 6
hours) favoring maximum sample integrity. All sample preparation
steps are automated: separation of plasma from the cellular fraction,
red blood cells lysis and removal, white blood cells dispensation and
fixation on SBS slides and plasma recovery in tubes. At the end of
the process, SBS slides with a fixed monolayer of all white blood
cells are made available, and the relative plasma aliquot is provided
in a separate tube. Both specimens are perfectly stable for several
days, having received minimum manipulation, contamination or shear
stress before stabilization.
The platform will be showcased at the upcoming Liquid Biopsy
conference organized by the European Association for Cancer Research
(EACR) in Bergamo, Italy, from May 24th to 26th.
"This is a key development milestone not just for Tethis but
hopefully for liquid biopsy adoption" said Mr. Gian Martino Franchi,
Chief Technology Officer of the company. "We have leveraged on our
proprietary nanocoated slides that allow immediate, spontaneous and
gentle adhesion of normally non adherent cells, to develop a fully
automated platform that not only fixes all white blood cells for
enrichment-free rare cell detection, but also provides a perfectly
stable plasma fraction for cell-free content analysis, allowing to
have an optimal preparation of all relevant content for liquid biopsy
testing. This is a first of its kind, and we trust that it can
contribute to the long-awaited standardization of blood processing
for liquid biopsies. We've been closely working with our partner MACS
srl for the development of this first release, and we have already
started planning the next generation platform that will further
enhance easiness of use, efficiency and throughput"
SBS slides are compatible with all analytical pathology techniques,
including cytology, immunocytochemistry (ICC), Immunofluorescence
(IF), Fluorescence in Situ Hybridization (FISH), for morphological
and biomarker-based analysis through brightfield or fluorescence
image acquisition. The extremely efficient cell adhesion and the
preserved morphology, together with the optimal distribution of the
cells on the slides as a monolayer, allows the implementation of AI
supported digital imaging for automated and efficient detection,
classification and profiling of rare circulating tumor cells as well
as of the immune cell compartment. Furthermore, identified cells can
be recovered through microdissection for downstream molecular
analysis at single cell level.
Plasma – on the other hand - is stable for several days with no need
for freezing and ready for cfNA extraction without any further
centrifugation step. The lean and automated processing provides
uncontaminated, standardized plasma for high quality, reproducible
downstream analysis of cell-free content.
"We are thrilled to introduce this novel solution to the market" said
Ms. Roberta Carbone, Ph.D, Tethis' Chief Scientific Officer. "It's a
first step towards true multi-analytical, standardized liquid biopsy
tests involving all possible tumor content released in the
bloodstream. We are now working on the validation for CE-IVD marking
of the platform and on the development of novel liquid biopsy tests
to bring to patients and at-risk individuals, but we also welcome
diagnostics industry players and drug developers who want to exploit
the optimal and comprehensive preparation guaranteed by See.d® for
the development of new tests and companion diagnostics or for
patients' stratification in clinical trials"
See.d® and SBS slides are for Research Use Only, not for use in
ABOUT TETHIS Tethis S.p.A is based in Milan, Italy, and is developing
a novel workflow to bring liquid biopsy in the clinical practice for
the precise management of cancer. Tethis' technology points to
standardization of the blood sample preparation to provide the
highest quality and integrity of liquid biopsy specimens for the
comprehensive analysis of all clinically informative biomarkers. The
company's proprietary nanocoated slides combined with the automated
pre-analytical instrument allow to identify and characterize rare
cells in blood, like circulating tumor cells, with unprecedented
sensitivity, also in early-stage settings.
Further information is available on the company's website,
Photo - https://mma.prnewswire.com/media/1818232/Tethis_1.jpg
Logo - https://mma.prnewswire.com/media/1818233/Tethis_Logo.jpg
Digital press kit: http://www.ots.at/pressemappe/PR163134/aom
Christian Drastil: Wiener Börse Plausch
Wiener Börse Plausch S2/60: Happy AT&S, Happy Do&Co, Happy Max Deml, Sohn Tobias punktet mit GameStop
Aktien auf dem Radar:S Immo, EVN, voestalpine, Warimpex, Amag, Immofinanz, Cleen Energy, AMS, Athos Immobilien, Erste Group, Polytec Group, Rath AG, Rosenbauer, Josef Manner & Comp. AG, Flughafen Wien, Oberbank AG Stamm, Semperit, Addiko Bank, DO&CO, Fresenius Medical Care, Fresenius, Deutsche Bank, Puma, SAP, Covestro, BASF, Bayer, MTU Aero Engines, Porsche Automobil Holding, Volkswagen Vz., SMA Solar.
Montana Aerospace zählt dank ihrer globalen Präsenz in Entwicklung und Fertigung sowie ihrer Multimaterial-Kompetenz zu den weltweit führenden Herstellern von komplexen Leichtbaukomponenten und Strukturen für die Luftfahrtindustrie. Als hochgradig integrierter Komplettanbieter mit State-of-the-Art-Fertigungsstätten in Europa, Amerika und Asien unterstützen wir die Local-to-Local-Strategie unserer Kunden.
>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER